Letairis and Chemotherapy - a phase IV clinical study of FDA data

Summary:

Chemotherapy is reported as a side effect among people who take Letairis (ambrisentan), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Adcirca, and have Systemic sclerosis (scleroderma).

The phase IV clinical study analyzes which people have Chemotherapy when taking Letairis. It is created by eHealthMe based on reports of 93,991 people who have side effects when taking Letairis from the FDA, and is updated regularly.

What is Letairis?

Letairis has active ingredients of ambrisentan. It is often used in pulmonary hypertension. eHealthMe is studying from 94,041 Letairis users. Check the latest studies of Letairis.

What is Chemotherapy?

Chemotherapy is found to be associated with 225 drugs and 468 conditions by eHealthMe. Check the latest studies of Chemotherapy.

On Jul, 13, 2026

93,991 people reported to have side effects when taking Letairis.
Among them, 45 people (0.05%) have Chemotherapy.

Among these 45 people:

How long have people been on Letairis when they have Chemotherapy? *

What is the gender of people who have Chemotherapy when taking Letairis? *

female: 61.9 %
male: 38.1 %

What is the age of people who have Chemotherapy when taking Letairis? *

What are other drugs people take besides Letairis? *

What are other side effects people have besides Chemotherapy? *

Dyspnea (difficult or laboured breathing): 5 people, 11.11%
Abdominal Pain Upper: 5 people, 11.11%
Fatigue (feeling of tiredness): 4 people, 8.89%
Nausea (feeling of having an urge to vomit): 4 people, 8.89%
Pain: 4 people, 8.89%
Muscle Aches (muscle pain): 4 people, 8.89%
Back Pain: 4 people, 8.89%
Death: 4 people, 8.89%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 6.67%
Chest Pain: 3 people, 6.67%

What are the existing conditions these people have? *

Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 3 people, 6.67%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 1 person, 2.22%
Pulmonary Radiation Injury: 1 person, 2.22%
Prostate Cancer: 1 person, 2.22%
Mixed Connective Tissue Disease (an autoimmune disease, in which the body's defence system attacks itself): 1 person, 2.22%
Diabetes: 1 person, 2.22%

* Approximation only. Some reports may have incomplete information.

Do you take Letairis and have Chemotherapy?

- Check whether Chemotherapy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Letairis:

Letairis (94,041 reports)

Chemotherapy treatments and more:

Chemotherapy (40,256 reports)

Browse all side effects of Letairis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chemotherapy:

Chemotherapy (225 drugs)

Browse all the conditions that are associated with Chemotherapy:

Chemotherapy (468 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ambrisentan (the active ingredients of Letairis) and Letairis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.